Cabergoline

Antiparkinsonian Drug

Drug class: Dopaminergic Antiparkinsonian Agent; Prolactin Inhibitor

Cabergoline (DOSTINEX)（中文：卡麥角林）

Common Strengths

• 0.5 mg

Drug Trade Names

• Dostinex

Drug Usage

Cabergoline is utilized for:

• Treating hyperprolactinemia (high prolactin levels).
• Managing prolactinomas (tumors that produce prolactin).
• Adjunct therapy in Parkinson's disease.

Mechanism of Action

Cabergoline works by stimulating dopamine D2 receptors, which inhibits the secretion of prolactin from the pituitary gland. This action helps normalize prolactin levels and can improve symptoms related to hyperprolactinemia and certain cases of Parkinson's disease.

Route of Administration

Cabergoline is administered orally in tablet form.

Dosages

• Initial dose: 0.25 mg twice weekly
• Maximum dose: 1 mg twice weekly

Side Effects

Frequency	Adverse reactions
Common Side Effects	Nausea, vomiting, dizziness, fatigue, and abdominal pain.
Serious Side Effects	Cardiac valvopathy, pulmonary fibrosis, severe hypotension, and compulsive behaviors (e.g. gambling)

Pharmacokinetics

• Onset of Action: Typically, within a few hours after administration.
• Duration of Action: Long-lasting effects, allowing for dosing twice weekly.
• Half-life: Approximately 63 to 109 hours after oral administration.

Drug Precautions

Pregnancy

The safety of cabergoline during pregnancy is not well established.

Breastfeeding

Cabergoline is not recommended during breastfeeding due to its potential effects on milk production.

Children and Elderly

Use in children requires careful consideration and monitoring. In elderly patients, increased sensitivity to side effects may occur; dosage adjustments may be necessary.